查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615420

基因生物标誌物市场：按产品类型、适应症和最终用户划分 - 2025-2030 年全球预测

Genomic Biomarker Market by Product (Consumables, Services, Software), Type (Predictive Biomarkers, Prognostic Biomarkers), Disease Indication, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

基因生物标誌物市场2023年估值为44亿美元，预计到2024年将达到46.7亿美元，复合年增长率为6.67%，预计到2030年将达到69.2亿美元。

基因生物标誌物是用于测量和评估生物过程和反应的 DNA/RNA 特征，对于透过实现个人化治疗方法来推进精准医学至关重要。慢性病盛行率的不断上升、精准医学研究的激增以及向个人化医疗解决方案的转变推动了对基因生物标誌物的需求。这些生物标记在个人化医疗、疾病诊断、药物开发和风险评估方面有着重要的应用。最终用途包括肿瘤学、心臟代谢疾病、神经病学和感染疾病，提供量身定制的健康解决方案，以改善患者的治疗效果并降低医疗成本。市场成长受到次世代定序仪等技术进步、个人化医疗需求不断增长以及製药和生物技术公司投资增加的影响。各国政府也透过战略资助和法律规范支持来促进研究和发展。然而，基因组技术的高成本、有关遗传资料隐私的伦理问题以及生物标记检验的复杂性等挑战可能会阻碍市场成长。基因组学的不断发展需要强大的计算工具和方法来分析复杂的资料集，这是创新的关键领域。精准肿瘤学透过基因生物标誌物指导最佳的癌症治疗，有可能带来显着的益处。有开发具有成本效益的解决方案和即时检测创新的机会，并且促进生物技术公司和学术机构之间的合作可以加快临床实施。竞争格局显示出不断增加的合併和策略联盟趋势，以扩大技术组合和市场覆盖范围。专注于技术整合和解决资料隐私问题可以为成功铺平道路。在创新、监管变化和基因组学知识库进步的推动下，市场动态不断变化且快速发展，为旨在生物製药行业长期永续性和竞争优势的投资提供了强大的机会。

主要市场统计
基准年[2023] 44亿美元
预测年份 [2024] 46.7亿美元
预测年份 [2030] 69.2亿美元
复合年增长率（%） 6.67%

市场动态：揭示快速发展的基因生物标誌物市场的关键市场洞察

供需的动态交互作用正在改变基因生物标誌物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 扩大基因生物标誌物在慢性病早期检测与诊断的应用
    • 政府和监管调查协助
    • 扩大基因生物标誌物在个人化医疗中的使用
  • 市场限制因素
    • 与基因生物标誌物开发相关的高成本和技术问题
  • 市场机会
    • 将人工智慧和机器学习与基因组研究结合
    • 人们对先进的非侵入性基因生物标誌物开发越来越感兴趣
  • 市场挑战
    • 关于使用基因生物标誌物的伦理和法律问题

波特的五力：驾驭基因生物标誌物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基因生物标誌物市场的外部影响

外部宏观环境因素在塑造基因生物标誌物市场的动态表现方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解基因生物标誌物市场的竞争状况

对基因生物标誌物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵基因生物标誌物市场供应商的绩效评估

FPNV定位矩阵是评估基因生物标誌物市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製基因生物标誌物市场的成功之路

基因生物标誌物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 更多地使用基因生物标誌物来早期检测和诊断慢性疾病
      • 政府和监管部门对基因生物标誌物研究的支持
      • 扩大基因生物标誌物在个人化医疗的应用
    • 抑制因素
      • 与开发基因生物标誌物相关的高成本和技术问题
    • 机会
      • 整合人工智慧、机器学习和基因组研究
      • 人们对开发先进的非侵入性基因生物标誌物越来越感兴趣
    • 任务
      • 关于使用基因生物标誌物的伦理和法律问题
  • 市场区隔分析
    • 类型：扩大预后生物标记在药物研究中的使用
    • 最终使用者：扩大基因生物标誌物在诊断中心的应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章基因生物标誌物市场：副产品

  • 消耗品
  • 服务
  • 软体

第七章基因生物标誌物市场：依类型

  • 预测性生物标记
  • 预后生物标记

第八章基因生物标誌物市场：依疾病指示

  • 心血管疾病
  • 神经系统疾病
  • 肿瘤学
  • 肾臟疾病

第 9 章基因生物标誌物市场：依最终用户分类

  • 诊断中心
  • 医院
  • 调查机构

第10章美洲基因生物标誌物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区基因生物标誌物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的基因生物标誌物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Bio-Rad 推出创新的多重数位 PCR 检测以增强乳癌监测
    • 使用 Biofidelity 的 ASPYRE-Lung RUO 试剂增强快速基因生物标誌物分析简介
    • Illumina 在肿瘤学领域取得突破 TruSight Oncology 500 ctDNA v2 为固态肿瘤基因组分析提供支持
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • APIS Assay Technologies Limited
  • Augurex Life Sciences Corp
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocrates Life Sciences AG
  • Biostarks Laboratories SA
  • Bruker Corporation
  • CD Genomics
  • Charles River Laboratories, Inc.
  • DH Life Sciences, LLC.
  • Elo Health, Inc.
  • Eurofins Scientific corporation
  • F. Hoffmann-La Roche Ltd
  • Illumina Inc.
  • Merck KGaA
  • Myriad Genetics, Inc
  • Owkin, Inc
  • Thermo Fisher Scientific company
Product Code: MRR-CB04E0565332

The Genomic Biomarker Market was valued at USD 4.40 billion in 2023, expected to reach USD 4.67 billion in 2024, and is projected to grow at a CAGR of 6.67%, to USD 6.92 billion by 2030.

Genomic biomarkers are DNA/RNA signatures used to measure and evaluate biological processes or responses, pivotal in driving precision medicine advances by enabling individualized therapeutic approaches. The need for genomic biomarkers is driven by the increasing prevalence of chronic diseases, a surge in precision medicine research, and the shifts towards personalized healthcare solutions. These biomarkers find significant applications in personalized medicine, disease diagnosis, drug discovery and development, and risk assessment. Their end-use spans across oncology, cardio-metabolic disorders, neurology, and infectious diseases, providing tailored health solutions to improve patient outcomes and reduce healthcare costs. Market growth is influenced by technological advancements like next-gen sequencing, rising demand for personalized medicine, and increased investments by pharmaceutical and biotech companies. Governments are also fostering R&D through strategic funding and supportive regulatory frameworks. However, challenges such as high costs of genomic technologies, ethical concerns related to genetic data privacy, and the complexity of biomarker validation may hinder market growth. The constant evolution of genomics necessitates robust computational tools and methodologies to analyze complex datasets, representing a significant innovation area. Precision oncology can benefit greatly, where genomic biomarkers guide optimal cancer therapies. Opportunities lie in developing cost-effective solutions and point-of-care testing innovations, encouraging collaborations between biotech firms and academic institutions to expedite clinical implementations. The competitive landscape shows an increasing trend of mergers and strategic alliances to broaden technology portfolios and market reach. Focusing on technology integration and addressing data privacy concerns can forge a successful path forward. The nature of the genomic biomarker market is dynamic and rapidly evolving, driven by innovation, regulatory changes, and the progressing knowledge base in genomics, providing a potent platform for investments aiming at long-term sustainability and competitive advantage in the biopharmaceutical industry.

KEY MARKET STATISTICS
Base Year [2023] USD 4.40 billion
Estimated Year [2024] USD 4.67 billion
Forecast Year [2030] USD 6.92 billion
CAGR (%) 6.67%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genomic Biomarker Market

The Genomic Biomarker Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
    • Governments and regulatory support for genomic biomarker research
    • Growing applications of genomic biomarkers in personalized medicine
  • Market Restraints
    • High cost and technical issues associated with developing genomic biomarkers
  • Market Opportunities
    • Integration of AI and machine learning with genomic studies
    • Growing interest in developing advanced noninvasive genomic biomarkers
  • Market Challenges
    • Ethical and legal concerns regarding the use of genomic biomarkers

Porter's Five Forces: A Strategic Tool for Navigating the Genomic Biomarker Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genomic Biomarker Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genomic Biomarker Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genomic Biomarker Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genomic Biomarker Market

A detailed market share analysis in the Genomic Biomarker Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genomic Biomarker Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genomic Biomarker Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genomic Biomarker Market

A strategic analysis of the Genomic Biomarker Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genomic Biomarker Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biocrates Life Sciences AG, Biostarks Laboratories SA, Bruker Corporation, CD Genomics, Charles River Laboratories, Inc., DH Life Sciences, LLC., Elo Health, Inc., Eurofins Scientific corporation, F. Hoffmann-La Roche Ltd, Illumina Inc., Merck KGaA, Myriad Genetics, Inc, Owkin, Inc, and Thermo Fisher Scientific company.

Market Segmentation & Coverage

This research report categorizes the Genomic Biomarker Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Consumables, Services, and Software.
  • Based on Type, market is studied across Predictive Biomarkers and Prognostic Biomarkers.
  • Based on Disease Indication, market is studied across Cardiovascular Diseases, Neurological Diseases, Oncology, and Renal Disorders.
  • Based on End-User, market is studied across Diagnostic Centers, Hospitals, and Research Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of genomic biomarkers in early detection and diagnosis of chronic disease
      • 5.1.1.2. Governments and regulatory support for genomic biomarker research
      • 5.1.1.3. Growing applications of genomic biomarkers in personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and technical issues associated with developing genomic biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of AI and machine learning with genomic studies
      • 5.1.3.2. Growing interest in developing advanced noninvasive genomic biomarkers
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical and legal concerns regarding the use of genomic biomarkers
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Proliferating use of prognostic biomarkers in pharmaceutical research
    • 5.2.2. End-user: Expanding application of genomic biomarkers in diagnostic centers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genomic Biomarker Market, by Product

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Services
  • 6.4. Software

7. Genomic Biomarker Market, by Type

  • 7.1. Introduction
  • 7.2. Predictive Biomarkers
  • 7.3. Prognostic Biomarkers

8. Genomic Biomarker Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Diseases
  • 8.3. Neurological Diseases
  • 8.4. Oncology
  • 8.5. Renal Disorders

9. Genomic Biomarker Market, by End-User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals
  • 9.4. Research Institutions

10. Americas Genomic Biomarker Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Genomic Biomarker Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Genomic Biomarker Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Bio-Rad Introduces Revolutionary Multiplexed Digital PCR Assay for Enhanced Breast Cancer Research
    • 13.3.2. Biofidelity's Introduction ASPYRE-Lung RUO Reagents for Enhanced and Rapid Genomic Biomarker Analysis
    • 13.3.3. Illumina's Breakthrough in Oncology TruSight Oncology 500 ctDNA v2 Enhances Solid Tumor Genomic Profiling
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. APIS Assay Technologies Limited
  • 4. Augurex Life Sciences Corp
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Bio-Techne Corporation
  • 7. Biocrates Life Sciences AG
  • 8. Biostarks Laboratories SA
  • 9. Bruker Corporation
  • 10. CD Genomics
  • 11. Charles River Laboratories, Inc.
  • 12. DH Life Sciences, LLC.
  • 13. Elo Health, Inc.
  • 14. Eurofins Scientific corporation
  • 15. F. Hoffmann-La Roche Ltd
  • 16. Illumina Inc.
  • 17. Merck KGaA
  • 18. Myriad Genetics, Inc
  • 19. Owkin, Inc
  • 20. Thermo Fisher Scientific company

LIST OF FIGURES

  • FIGURE 1. GENOMIC BIOMARKER MARKET RESEARCH PROCESS
  • FIGURE 2. GENOMIC BIOMARKER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENOMIC BIOMARKER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENOMIC BIOMARKER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENOMIC BIOMARKER MARKET DYNAMICS
  • TABLE 7. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY PROGNOSTIC BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RENAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENOMIC BIOMARKER MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENOMIC BIOMARKER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENOMIC BIOMARKER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENOMIC BIOMARKER MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. GENOMIC BIOMARKER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENOMIC BIOMARKER MARKET, FPNV POSITIONING MATRIX, 2023